CD274 and liver cancer: Tomoko’s team (9) also conducted a clinical study of lenvatinib treatment after failure of PD-1/PD-L1 treatment for liver cancer, finding that the mPFS after lenvatinib treatment was 10 months, mOS was 15.8 months, ORR reached 55.6%, and Disease control rate (DCR) reached 86.1%.